Nokia Corp vs Relay Therapeutics Inc. Common Stock — how do they compare? Nokia Corp trades at $10.26 (market cap $60.13B), while Relay Therapeutics Inc. Common Stock trades at $17.5 (market cap $3.94B). The key difference: Nokia Corp is far larger — about 15.3× Relay Therapeutics Inc. Common Stock's market cap, and Nokia Corp pays a 1.54% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 66 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| NOK | RLAY | |
|---|---|---|
Market Cap | $60.13B | $3.94B |
Volume | 71,806,452 | 3,432,928 |
Sector | Technology | Health |
52-Week High | $16.83 | $20.75 |
52-Week Low | $5.18 | $6.03 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $58.14B | $3.06B |
Dividend Yield | 1.54% | — |
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.62, down 3.19% on the day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights a strategic partnership with Microsoft for AI-driven network automation and sovereign satellite network development with ICEYE, positioning Nokia in high-growth infrastructure segments.
The outlook is supported by strong analyst sentiment with a consensus price target of $17.50, implying significant upside. Key opportunities include expanding AI and cloud orders, while risks involve competitive pressures and execution challenges in integrating new technologies. Cash flow volatility and a high P/E ratio of 78.9 warrant caution, but institutional buy ratings suggest confidence in long-term growth.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →